Park Square is pleased to announced the placement of Norman Greenberg, Ph.D., as Executive Vice President, New Initiatives at Prellis Biologics. Prellis is a pioneering tissue engineering company that uses cutting-edge optical engineering technology to print ultra-fine biomimetic tissue scaffolds for use in organ development, tissue engineering research, and therapeutic development.

Greenberg is a highly accomplished cancer immunotherapy researcher and drug developer. Prior to joining Prellis, Greenberg served as Chief Scientific Officer at Atreca, a publicly traded biopharmaceutical company developing a novel portfolio of antibody therapeutics. Previously, he served as Senior Vice President, Translational Medicine at Checkmate Pharmaceuticals. Earlier in his career, Greenberg served as Vice President, Research and Development at MedImmune, where he led the company’s oncology research therapeutic area on a global basis. He began his career in tenured faculty positions at Baylor College of Medicine and the Fred Hutchinson Cancer Research Center.

Greenberg received his B.S. in Microbiology and Immunology from University of Toronto and his Ph.D. in Microbiology and Immunology from University of British Columbia.

Park Square Executive Search serves companies and institutions that are shaping the world through discovery, innovation and growth. Our clients are leading life sciences and healthcare organizations, technology companies, major research universities, and venture capital and private equity firms, including their portfolio companies. We place board members, chief executive officers, C-suite executives, and academic leaders.